Collaborative research on early detection of colorectal cancer unveiled at AGBT
AccuraGen unveil edits result of the collaborative research on the early detection of colorectal cancer at AGBT this year. The studywas undertaken by Shanghai Yunsheng Medical Laboratory (fully owned subsidiary of AccuraGen Holdings), and was carried out for many years in cooperation with the team led by Dr Zhiqian Hu, director of anorectal surgery, Shanghai Changzheng Hospital. The results were presented in the form of a poster, with a focus using amplicon methods to obtain mutation and fragment information in circulating tumor DNA (ctDNA), for early detection of colorectal cancer.
This research deploys a highly efficient ssDNA sequencing technology(CLAmp-seq),which combines rolling cycle amplification of circularized cfDNA molecules with concatemer based error correction. This research analyzes mutation and fragment information with >1,000 healthy and colorectal cancer cohort. While somatic mutation is always used to infer the identity of tumor-derived circulating DNA, fragment information from cfDNA molecule is recently explored to increase the sensitivity of cancer detection when mutation information is not available.